Sage Therapeutics - Articles and news items

SAGE achieves 77% response rate in Phase 1/2 clinical trial of SAGE-547 in super-refractory status epilepticus

Industry news / 15 May 2015 / Victoria White

SAGE-547 demonstrated robust activity, with a 77% response rate in patients with SRSE, in a successfully completed Phase 1/2 clinical trial…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+